Association Between HIV Infection and Cancer Stage at Presentation at the Uganda Cancer Institute

Purpose The HIV epidemic has contributed to the increasing incidence of cancer in sub-Saharan Africa, where most patients with cancer present at an advanced stage. However, improved access to HIV care and treatment centers in sub-Saharan Africa may facilitate earlier diagnosis of cancer among patients who are HIV positive. To test this hypothesis, we characterized the stage of cancer and evaluated the factors associated with advanced stage at presentation among patients in Uganda.

Methods We conducted a retrospective analysis of adult patients with any of four specific cancers who presented for care in Kampala, Uganda, between 2003 and 2010. Demographic, clinical, and laboratory data were abstracted from the medical record, together with the outcome measure of advanced stage of disease (clinical stage III or IV). We identified measures for inclusion in a multivariate logistic regression model.

Results We analyzed 731 patients with both AIDS-defining cancers (cervical [43.1%], and non-Hodgkin lymphoma [18.3%]), and non-AIDS-defining cancers (breast [30.0%] and Hodgkin lymphoma [8.6%]). Nearly 80% of all patients presented at an advanced stage and 37% had HIV infection. More than 90% of patients were symptomatic and the median duration of symptoms before presentation was 5 months. In the multivariate model, HIV-positive patients were less likely to present at an advanced stage as were patients with higher hemoglobin and fewer symptoms.

Conclusion Patients with limited access to primary care may present with advanced cancer because of a delay in diagnosis. However, patients with HIV now have better access to clinical care. Use of this growing infrastructure to increase cancer screening and referral is promising and deserves continued support, because the prognosis of HIV-positive patients with advanced cancer is characterized by poor survival globally.

INTRODUCTION

The incidence of cancer is increasing globally, with nearly 14 million new cases diagnosed in 2012.1 The burden of cancer is growing in sub-Saharan Africa (SSA), where an estimated 766,000 incident cancer cases and 587,000 cancer deaths are projected to occur in 2020, an increase of approximately 40% over 2008.1 This problem is particularly noteworthy given the prevalence of concomitant HIV infection in SSA because infection with HIV is associated with an increased risk of a variety of malignancies, likely in part because of systemic immunosuppression.2 Although the increased risk is most pronounced for malignancies caused by oncogenic infections (eg, Kaposi’s sarcoma; anogenital cancers; or certain subtypes of non-Hodgkin lymphoma [NHL] including Burkitt’s lymphoma, primary CNS lymphoma, and primary effusion lymphoma), the risk persists for many cancers.3,4 Fortunately, the incidence of many cancers among HIV-infected individuals is declining,5,6 possibly because of an effective combination antiretroviral therapy (cART) that assists in immune reconstitution and the prevention of severe immunosuppression.7 However, HIV-infected patients are still typically diagnosed at a later stage, with worse outcomes than uninfected patients with cancer.8

In low- and middle-income countries, including those in SSA, the majority of patients with cancer, independent of HIV status, present to care at an advanced stage. Although there is clearly variability among countries in SSA, one factor responsible for the late stage at presentation is secondary to a limited health care infrastructure that precludes access to timely clinical care and the resulting lack of medical surveillance.9-12 Similarly, in the
in the United States, in a study linking cancer registry data with registry data from HIV and AIDS and solid-organ transplant populations, both of which are immunosuppressed groups, it was observed that HIV-infected patients were more likely to present at an advanced stage of lung, breast, and prostate cancer than were immunocompetent patients. In contrast, solid-organ transplant patients were more likely to present with early-stage cancer than were immunocompetent patients, suggesting a potential role of medical surveillance and increased vigilance among transplant recipients. In large part because of funding from the Global Fund for AIDS, TB, and Malaria and the US President’s Emergency Fund for AIDS Relief (PEP-FAR), access to HIV care and treatment, including the availability of cART, has increased dramatically in SSA. As such, HIV-infected patients now likely have improved access to clinical care, as well as access to cART, and therefore may benefit from stricter medical follow-up. The benefit of such vertical programmatic efforts on other health outcomes, including cancer, is uncertain. A recent retrospective longitudinal study in Uganda did not reveal any significant changes in non-HIV service use despite PEPFAR investments in strengthening health systems; however, data from other countries have been encouraging. Therefore, we hypothesize that HIV-infected patients with cancer present to care at an earlier stage than do their uninfected counterparts and that by using the HIV care infrastructure, clinical outcomes may be improved. Here we describe the association between HIV status, and other patient characteristics, and advanced stage of cancer at diagnosis among patients presenting for care in Uganda.

METHODS

We conducted an analysis of adult (>18 years of age) residents of Kyadondo County (Uganda) who were diagnosed with breast cancer, cervical cancer, NHL, or Hodgkin lymphoma (HL) between 2003 and 2010 as part of a retrospective cohort study described previously. Cases were identified from the Kampala Cancer Registry, a population-based cancer registry covering the capital city, Kampala, and the surrounding peri-urban regions. Data from the Kampala Cancer Registry were reconciled with clinical data from a national teaching hospital in Kampala, Uganda (Mulago Hospital) and the adjacent Uganda Cancer Institute (UCI), the nation’s only cancer center. The four malignancies analyzed here represent cancers typically associated with an infection (ie, cervical cancer and human papilloma virus, certain subtypes of NHL and Epstein-Barr virus, HL and Epstein-Barr virus) and a cancer with no known association with infection (ie, breast cancer). In addition, we deliberately included both AIDS-defining cancers (ie, cervical and NHL) and non–AIDS-defining cancers (ie, HL and breast). Finally, we assessed cancers that were a particular burden in Uganda; cervical and breast cancer represent the most common and the second most common cause of cancer and cancer-related deaths among women in Uganda, respectively. Only patients with a new diagnosis of cancer were included; patients with relapsed or refractory disease were excluded.

We abstracted demographic and clinical data from the medical record. Clinical data included a review of symptoms, duration of symptoms, medical history (including medications and comorbid conditions), and physical examination. Separate composite measures of the number of symptoms (ie, symptom score) and coexisting medical illness (ie, comorbidity index) were created; each individual symptom or illness was given the same weight. Laboratory data included blood counts and metabolic measurements when available. Anemia was defined as a hemoglobin level <11 g/dL per the WHO definition. The stage at presentation, assessed typically via an abdominal ultrasound and/or a chest radiograph, was dichotomized as nonadvanced or advanced stage and was categorized as per standard clinical staging systems. For both HL and NHL, nonadvanced disease included either the involvement of a single lymph node region (stage I) or the presence of two or more lymph node regions on the same side of the diaphragm (stage II). Advanced disease was characterized by involvement of lymph node regions on both sides of the diaphragm (stage III) or by diffuse disease (stage IV). For cervical cancer, nonadvanced disease was limited to invasion beyond the uterus but not to the pelvic wall or lower third of the vagina; extension to the lower third of the vagina or the presence of any nodal disease was characterized as advanced stage as per the International Federation of Gynecology and Obstetrics. Breast cancer staging was per the American Joint Commission on Cancer. The presence of any nodal involvement, with the exception of ipsilateral axillary nodes in the setting of a small primary tumor (ie, <20 mm), was characterized as advanced disease. In addition, any tumor involvement with direct extension to the chest wall or skin, independent of nodal status, was characterized as advanced disease. In the event that clinical stage was not recorded in the medical record, a study
physician at the UCI reviewed the medical record and assigned a clinical stage.

HIV status was ascertained by either the results of HIV antibody testing, documentation of care at a local HIV treatment facility, or documentation of HIV status in the clinical notes.

The primary outcome measure was advanced stage of disease (ie, stage III or IV) at presentation. Using logistic regression models, we assessed whether infection with HIV, as well as whether other demographic, clinical, and laboratory measurements, were associated with stage. Variables with a P value < .20 in the bivariate model were included in the multivariate logistic regression analysis.21 These models were used for each individual malignancy as well as for the total patient sample overall.

The study was approved by the Makerere University College of Health Sciences Research Ethics Committee (Kampala, Uganda) and by the Fred Hutchinson Cancer Research Center’s institutional review board (Seattle, WA).

RESULTS

A total of 731 patients were included in this analysis, including 315 women with cervical cancer, 219 patients with breast cancer, 134 patients with NHL, and 63 patients with HL. The median age of all patients was 43 years (18 to 86 years), with little variation by cancer type (Table 1).

More than one half of patients with either NHL (77 [57.5%]) or HL (35 [55.6%]) were HIV infected, whereas 42.5% of women with cervical cancer were HIV infected (n = 134); a lower percentage of patients with breast cancer were HIV infected (24 [11.0%]) compared with patients with the other cancers studied. Overall, 525 (79.6%) presented at an advanced stage of disease. Approximately 70% of women with cervical cancer (199 [68%]) and patients with HL (44 [71%]) presented at an advanced stage, whereas nearly 90% of patients with breast cancer (181 [93.3%]) and NHL (111 [88.1%]) were diagnosed with advanced disease at presentation (Table 1).

At the time of initial presentation, patients presented with a median of two symptoms (range, zero to nine symptoms); these symptoms were present for a median of 5 months before presentation (range, 0 to 96 months). Although women with breast cancer presented with a median of one symptom at presentation, the median duration was 9 months (range, 1 to 72 months) before presentation (Table 1). More than one half of the patients with NHL (72 [53.7%]), HL (37 [59.7%]), and cervical cancer (132 [60.0%]) were anemic at presentation; a slightly lower percentage of patients with breast cancer (29.1% [34 patients]) were anemic. With the exception of tuberculosis, which was a coexisting illness among 14.9% of patients (n = 20) and 23.8% of patients (n = 15) with NHL and HL, respectively, other comorbidities were uncommon.

The association of the various demographic and clinical characteristics with advanced stage at diagnosis differed according to cancer type in our study cohort (Table 2). Among patients with breast cancer, an increased symptom score and a longer duration of symptoms before presentation were associated with advanced stage of disease in unadjusted analyses, with symptom score remaining significantly associated with advanced disease in adjusted models (odds ratio [OR], 19.5; 95% CI, 1.3 to 293.2). In the unadjusted analyses among women with cervical cancer, HIV-infected patients were more likely than were HIV-uninfected patients to present at an early stage; other factors included an older age, an increased symptom score, an increased comorbidity index, and lower hemoglobin, with only hemoglobin at the time of presentation remaining associated with advanced stage in adjusted models (OR, 0.81; 95% CI, 0.71 to 0.93). An increased symptom score and lower hemoglobin were associated with NHL in the adjusted analysis; however, neither of these factors was associated with advanced stage of disease. Among patients with HL, of the factors significant in the unadjusted analysis (increased symptom score, additional comorbidities, lower hemoglobin, and HIV infection), only HIV infection was significantly associated with the likelihood of presenting with advanced-stage disease.

Among all patients with cancer, HIV infection, older age, male sex, increased number of symptoms, longer symptom duration, and anemia were associated with advanced disease in the unadjusted analyses (Table 3). After adjusting for the other covariates, HIV-infected patients were more likely to present at an earlier stage for the entire sample (OR, 0.53; 95% CI, 0.30 to 0.94); however, this was driven largely by the relationship between HIV infection and advanced cervical cancer (OR, 0.62; Table 3 and Fig 1). In addition, each additional symptom (OR, 1.54; 95% CI, 1.18 to 2.03) and a lower hemoglobin (OR, 0.89; 95% CI, 0.80 to 0.99) were significantly associated with an increased odds of presenting at an advanced stage in the multivariate model (Table 3).
DISCUSSION

Patients with cancer in resource-poor settings often have limited access to primary care and may therefore delay presenting to cancer specialty care. In our cohort, nearly 80% of patients presented to care at an advanced stage. A host of factors, including both patient specific (ie, lack of patient awareness, perceived costs, and preference for traditional healers) and system related (ie, a weak health care infrastructure resulting in a lack of trained health care workers and diagnostics), have been documented previously as possibly responsible for the corresponding delay to care.22,23 Multiple studies have documented the negative impact of delays to diagnosis, including increased mortality.24-28 In a study of nearly 3,000 women with breast cancer, delays to care, defined as the presence of symptoms for >12 weeks before presentation were associated with inferior survival, an association caused by the relationship between advanced stage and delay.26

In our entire sample, nearly 80% of patients presented at an advanced stage, including >90% of women with breast cancer and nearly 70% of women with cervical cancer. Largely because of breast and cervical cancer screening, <20% of women with breast cancer and <10% of women with cervical cancer present with distant disease in the United States.29-31 Accordingly, in the United States, the 5-year survival rate ranges from 58% to 93% for early-stage cervical cancer compared with 15% to 35% for advanced-stage disease.20 Among patients with breast cancer, the 5-year survival for stage I disease approaches 100%, compared with 22% for patients with stage IV disease.20 Similarly, among our sample, nearly 90% of patients with NHL and 70% of patients with HL presented with advanced disease compared

Table 1. Demographic and Clinical Characteristics by Cancer Type (N = 731)

| Characteristic                      | Cervical (n = 315) | Breast (n = 219) | NHL (n = 134) | HL (n = 63) | Total (N = 731) |
|------------------------------------|-------------------|------------------|---------------|------------|----------------|
| Female, No. (%)                    | 315 (100)         | 215 (98.2)       | 60 (44.8)     | 34 (54.0)  | 624 (85.4)     |
| Age, years, median (range)         | 43 (20-84)        | 45 (19-86)       | 40 (19-82)    | 34 (18-80) | 43 (18-86)     |
| No. symptoms at presentation, median (range) | 2 (0-7)        | 1 (0-5)          | 3 (0-9)       | 3 (0-9)    | 2 (0-9)        |
| Symptom duration before presentation, months, median (range) | 4 (0-72)       | 9 (1-72)         | 4 (1-96)      | 5 (1-72)   | 5 (0-96)       |
| HIV-infected, No. (%)              | 134 (42.5)        | 24 (11.0)        | 77 (57.4)     | 35 (55.6)  | 270 (36.9)     |
| Anemic (HgB, 11g/dL) at presentation, No. (%) | 132 (60.0)      | 34 (29.1)        | 72 (53.7)     | 37 (59.7)  | 275 (51.6)     |
| Stage at presentation, No. (%)     |                   |                  |               |            |                |
| 1                                  | 13 (4.7)          | 7 (3.6)          | 4 (3.2)       | 6 (9.7)    | 30 (4.6)       |
| 2                                  | 76 (27.3)         | 6 (3.1)          | 11 (8.7)      | 12 (19.4)  | 105 (15.9)     |
| 3                                  | 162 (58.3)        | 129 (66.5)       | 48 (38.1)     | 29 (46.8)  | 368 (55.8)     |
| 4                                  | 27 (9.7)          | 52 (26.8)        | 63 (50.0)     | 15 (24.2)  | 157 (23.8)     |

Abbreviations: HgB, hemoglobin; HL, Hodgkin lymphoma; NHL, non-Hodgkin lymphoma.

Table 2. Factors Associated With Advanced Stage of Disease (stage III or IV) at Presentation by Cancer Type

| Factor                                      | Breast Cancer | Cervical Cancer | Non-Hodgkin Lymphoma | Hodgkin Lymphoma |
|---------------------------------------------|---------------|-----------------|----------------------|-----------------|
| Age, each additional month                  | 1.03 (0.99 to 1.07) |                 |                      |                 |
| Female sex                                  |               |                 |                      |                 |
| Symptom score at presentation, each additional symptom | 19.5 (1.29 to 293.2) | 1.10 (0.77 to 1.58) | 1.47 (0.93 to 2.31) | 1.51 (0.84 to 2.69) |
| Symptom duration before presentation, months, each additional month | 1.10 (0.96 to 1.26) |                 |                      |                 |
| Comorbidity score at presentation           | 1.17 (0.38 to 3.65) |                 | 1.07 (0.37 to 3.10) |                 |
| HIV infected                                | 0.62 (0.29 to 1.31) |                 | 3.88 (1.06 to 14.2) |                 |
| HgB at presentation, each unit increase g/dL | 0.81 (0.71 to 0.93) | 0.88 (0.71 to 1.10) | 0.91 (0.72 to 1.15) |                 |

NOTE. Data are presented as odds ratio (95% CI).
Abbreviation: HgB, hemoglobin.
with approximately 50% and 40% of patients with NHL and HL, respectively, in the United States.²⁹,³² Both the International Prognostic Index and the International Prognostic Score for NHL and HL document the adverse effect of advanced-stage disease.³³,³⁴ Although not validated prospectively, these relationships almost certainly exist in resource-limited areas as well. As such, efforts to identify patients at an earlier stage, when prognosis and treatment options are improved, are clearly warranted.

Among our sample, HIV-infected patients presented at an earlier stage than did their uninfected counterparts, a likely benefit of more timely clinical access and engagement. As such, one potential strategy to improve the early detection of cancer, and therefore downstage patients in resource-limited regions, is to strengthen the health care infrastructure by leveraging the strengths of vertical health programs via a diagonal approach.³⁵,³⁶ Given the high prevalence of concomitant HIV infection among patients at the UCI (eg, nearly 40% in our sample), efforts to integrate HIV care and treatment programs into cancer screening and early-detection programs would be beneficial. Multiple initiatives, including the Global Fund, PEPFAR, and the World Bank Multicountry AIDS Program, have dramatically increased the scale-up

### Table 3. Factors Associated With Advanced Stage of Disease (stage III or IV) at Presentation

| Factor                                      | Bivariate               | Multivariate            |
|---------------------------------------------|-------------------------|-------------------------|
|                                             | Odds Ratio  | 95% CI     | Odds Ratio  | 95% CI     |
| Age, each additional month                  | 1.03        | 1.01 to 1.04 | 1.02        | 1.00 to 1.04 |
| Female sex                                  | 0.64        | 0.36 to 1.14 | 0.76        | 0.38 to 1.54 |
| Symptom score at presentation, each additional symptom | 1.37        | 1.15 to 1.62 | 1.54        | 1.18 to 2.03 |
| Symptom duration before presentation, months, each additional month | 1.02        | 0.99 to 1.05 | 1.02        | 0.99 to 1.06 |
| Comorbidity score at presentation           | 1.63        | 1.04 to 2.56 | 1.26        | 0.73 to 2.18 |
| HIV infected                                | 0.51        | 0.35 to 0.74 | 0.53        | 0.30 to 0.94 |
| Hgb at presentation, each unit increase g/dL| 0.92        | 0.85 to 0.99 | 0.89        | 0.84 to 0.99 |

Abbreviation: Hgb, hemoglobin.

### Fig 1. Prevalence of HIV infection by cancer type and stage. (*) OR, 3.5; 95% CI, 1.10 to 11.1. (†) OR, 0.4; 95% CI, 0.26 to 0.73. (‡) OR, 0.5; 95% CI, 0.35 to 0.74. HL, Hodgkin lymphoma; NHL, non-Hodgkin lymphoma; OR, odds ratio.
of HIV-AIDS service delivery in SSA. Although these efforts have clearly had positive effects on reducing the incidence of HIV, a criticism of these vertical initiatives is that they may weaken the overall health system by increasing demand and decreasing the workforce via worker burnout.\textsuperscript{14,37,38}

In SSA, efforts to integrate health promotion activities, including family planning and making available safe water and childhood vaccinations, have been successful using the HIV care and treatment platform.\textsuperscript{39,40} Indeed, in a study of patients in HIV care and treatment centers in Ethiopia, the integration of basic care services aimed at improving sanitation and hygiene among HIV-infected patients receiving cART improved health outcomes (eg, lower rates of illness, less health facility visits).\textsuperscript{40} It is especially important to diagnose and treat HIV-infected patients early, given their increased cancer-specific mortality compared with that of uninfected individuals.\textsuperscript{8,41} Multiple studies have documented the increased mortality associated with cancer among HIV-infected patients both in resource-abundant and in resource-limited regions, likely secondary to both HIV-induced immunosuppression and the decreased likelihood of receiving cancer-directed therapy.\textsuperscript{10,42-45}

In addition to HIV infection, patients in our retrospective cohort with a higher symptom score (ie, a greater number of symptoms) and those with lower hemoglobin, both possibly suggestive of a greater disease burden, were more likely to present at an advanced stage. Although a patient’s functional status (eg, Eastern Cooperative Oncology Group performance status) has prognostic usefulness, it was not recorded routinely in these medical records.\textsuperscript{46,47} However, a recent cross-sectional study among patients with cancer in Botswana noted that the symptom burden, as measured by the Memorial Symptom Assessment Scale–Short Form, was significantly associated ($P < .01$) with the patient’s Eastern Cooperative Oncology Group performance status.\textsuperscript{38} It is unknown, however, whether the prognosis associated with increased symptoms or poor performance status is reflective of the biology of the disease or whether such symptoms preclude the use of cancer-directed therapy. Similarly, the presence of anemia among patients with terminal cancer has been shown previously to be associated with poor prognosis and early mortality.\textsuperscript{49-51} However, the direction of these associations is not clear. Although the association between anemia and poor health outcomes among patients with cancer is well documented, it is uncertain whether anemia is a marker for more aggressive or refractory disease, or whether anemia limits or affects treatment options (ie, delaying or deferring chemotherapy). Regardless, symptomatic patients would benefit from early clinical care; however, the health care infrastructure in SSA often precludes such clinical engagement.

Given the recent increase in HIV care and treatment centers in SSA, patients with HIV likely have improved access to clinical care. Although much of the integration of HIV care has been focused either on other infectious diseases or on maternal health, recent efforts have recognized the increasing burden of noncommunicable diseases in resource-limited regions. Because cervical cancer remains a leading cause of morbidity and mortality in SSA, with an increased incidence among HIV-infected women, limited efforts have begun to integrate cervical cancer screening programs within HIV treatment platforms. Using PEPFAR support, colleagues in Mozambique implemented a 1-year cervical cancer screening pilot program, via visual inspection with acetic acid, in four health facilities that provide cART. Although not performed routinely in SSA, visual inspection with acetic acid in this pilot study was positive in 380 of the 4,651 women screened (8%), the majority of whom had never been screened previously. Nine months after implementation, > 95% of women requiring treatment via cryotherapy received therapy on the day of screening, demonstrating a benefit of screening in early diagnosis and treatment.\textsuperscript{52} Using a computer simulation model, researchers estimated that cervical cancer screening at cART initiation would prevent one cervical cancer–related death for every 262 HIV-positive women screened in Cameroon.\textsuperscript{53} Although the number needed to screen in that analysis was higher than in an analysis of the United Kingdom National Cervical Screening Program, in which cervical cancer screening was found to prevent the death of one in 65 screened woman, it compares favorably to the screening benefit of mammography.\textsuperscript{54,55} Whereas the cost effectiveness of cervical cancer screening has been documented among women in resource-limited settings and among HIV-infected women in the United States, additional data regarding the cost effectiveness of cervical cancer screening among HIV-infected women in resource-limited regions are warranted.\textsuperscript{56,57}

Although future studies are necessary to evaluate cancer-specific predictors of advanced disease stage, leveraging the HIV care and treatment
infrastructure to increase cancer screening and referral, especially with regard to cervical cancer, is a promising and likely cost-effective method to diagnose cancer at an earlier stage. Because the prognosis of HIV-infected patients with advanced-stage cancer is characterized by poor survival, even in resource-abundant regions, such integrative efforts deserve continued support.

DOI: https://doi.org/10.1200/JGO.17.00005
Published online on jgo.org on October 16, 2017.

AUTHOR CONTRIBUTIONS
Conception and design: Manoj P. Menon, Anna Coghill, Warren T. Phipps, Fred M. Okuku, Jackson Orem, Corey Casper
Financial support: Corey Casper
Administrative support: Corey Casper
Provision of study material or patients: Fred M. Okuku
Collection and assembly of data: Manoj P. Menon, Anna Coghill, Fred M. Okuku, Jackson Orem, Corey Casper
Data analysis and interpretation: Manoj P. Menon, Innocent O. Mutyaba, Fred M. Okuku, John M. Harlan, Jackson Orem, Corey Casper
Manuscript writing: All authors
Final approval of manuscript: All authors
Accountable for all aspects of the work: All authors

AUTHORS’ DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST
The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO’s conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/jco/site/ifc.

Affiliations
Manoj P. Menon, Anna Coghill, Warren T. Phipps, and Corey Casper, Fred Hutchinson Cancer Research Center; Manoj P. Menon, Warren T. Phipps, John M. Harlan, and Corey Casper, University of Washington, Seattle, WA; and Innocent O. Mutyaba, Fred M. Okuku, and Jackson Orem, Uganda Cancer Institute, Kampala, Uganda.

Support
Supported by Career Development in Clinical Hematology Award 5 K12 HL 087165 (M.P.M.).

Prior Presentation
Presented in part at the 50th Annual Meeting of the American Society of Clinical Oncology, May 2014, Chicago, IL.

REFERENCES
1. International Agency for Research on Cancer: GLOBOCAN 2012: Estimated cancer incidence, mortality and prevalence worldwide in 2013. http://globocan.iarc.fr
2. Casper C: The increasing burden of HIV-associated malignancies in resource-limited regions. Annu Rev Med 62:157-170, 2011
3. Centers for Disease Control (CDC): Kaposi’s sarcoma and Pneumocystis pneumonia among homosexual men—New York City and California. MMWR Morb Mortal Wkly Rep 30:305-308, 1981
4. Patel P, Hanson DL, Sullivan PS, et al: Incidence of types of cancer among HIV-infected persons compared with the general population in the United States, 1992-2003. Ann Intern Med 148:728-736, 2008
5. van Leeuwen MT, Vajdic CM, Middleton MG, et al: Continuing declines in some but not all HIV-associated cancers in Australia after widespread use of antiretroviral therapy. AIDS 23:2183-2190, 2009
6. Robbins HA, Shiels MS, Pfeiffer RM, et al: Epidemiologic contributions to recent cancer trends among HIV-infected people in the United States. AIDS 28:881-890, 2014
7. Gantt S, Casper C, Ambinder RF: Insights into the broad cellular effects of nelfinavir and the HIV protease inhibitors supporting their role in cancer treatment and prevention. Curr Opin Oncol 25:495-502, 2013
8. Coghill AE, Shiels MS, Suneja G, et al: Elevated cancer-specific mortality among HIV-infected patients in the United States. J Clin Oncol 33:2376-2383, 2015
9. Kingham TP, Alatise OI, Vanderpuye V, et al: Treatment of cancer in sub-Saharan Africa. Lancet Oncol 14:e158-e167, 2013
10. Coghill AE, Newcomb PA, Madeleine MM, et al: Contribution of HIV infection to mortality among cancer patients in Uganda. AIDS 27:2933-2942, 2013
11. Cazap E, Magrath I, Kingham TP, et al: Structural barriers to diagnosis and treatment of cancer in low- and middle-income countries: The urgent need for scaling up. J Clin Oncol 34:14-19, 2016
12. Lopes LV, Miguel F, Freitas H, et al: Stage at presentation of breast cancer in Luanda, Angola: A retrospective study. BMC Health Serv Res 15:471, 2015
13. Shiels MS, Copeland G, Goodman MT, et al: Cancer stage at diagnosis in patients infected with the human immunodeficiency virus and transplant recipients. Cancer 121:2063-2071, 2015
14. Biesma RG, Brugha R, Harmer A, et al: The effects of global health initiatives on country health systems: A review of the evidence from HIV/AIDS control. Health Policy Plan 24:239-252, 2009
15. Luboga SA, Stover B, Lim TW, et al: Did PEPFAR investments result in health system strengthening? A retrospective longitudinal study measuring non-HIV health service utilization at the district level. Health Policy Plan 31:897-909, 2016
16. Lister TA, Crowther D, Sutcliffe SB, et al: Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin’s disease: Cotswolds meeting. J Clin Oncol 7:1630-1636, 1989
17. Cheson BD, Fisher RI, Barrington SF, et al: Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: The Lugano classification. J Clin Oncol 32:3059-3068, 2014
18. Armitage JO: Staging non-Hodgkin lymphoma. CA Cancer J Clin 55:368-376, 2005
19. Benedet JI, Bender H, Jones H III, et al: FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers. Int J Gynaecol Obstet 70:209-262, 2000
20. American Joint committee on Cancer: AJCC Cancer Staging Manual. New York, NY, Springer-Verlag, 2010.
21. Bursac Z, Gauss CH, Williams DK, et al: Purposeful selection of variables in logistic regression. Source Code Biol Med 3:17, 2008
22. Pruitt L, Mumuni T, Raikhel E, et al: Social barriers to diagnosis and treatment of breast cancer in patients presenting at a teaching hospital in Ibadan, Nigeria. Glob Public Health 10:331-344, 2015
23. Pace LE, Mpunga T, Hategekimana V, et al: Delays in breast cancer presentation and diagnosis at two rural cancer referral centers in Rwanda. Oncologist 20:780-788, 2015
24. Ermiah E, Abdalla F, Buhmeida A, et al: Diagnosis delay in Libyan female breast cancer. BMC Res Notes 5:452, 2012
25. Jung SY, Sereika SM, Linkov F, et al: The effect of delays in treatment for breast cancer metastasis on survival. Breast Cancer Res Treat 130:953-964, 2011
26. Richards MA, Smith P, Ramirez AJ, et al: The influence on survival of delay in the presentation and treatment of symptomatic breast cancer. Br J Cancer 79:858-864, 1999
27. Neal RD, Tharmanathan P, France B, et al: Is increased time to diagnosis and treatment in symptomatic cancer associated with poorer outcomes? Systematic review. Br J Cancer 112:S92-S107, 2015
28. Richards MA, Westcombe AM, Love SB, et al: Influence of delay on survival in patients with breast cancer: A systematic review. Lancet 353:1119-1126, 1999
29. Siegel RL, Miller KD, Jemal A: Cancer statistics, 2016. CA Cancer J Clin 66:7-30, 2016
30. Iqbal J, Ginsburg O, Rochon PA, et al: Differences in breast cancer stage at diagnosis and cancer-specific survival by race and ethnicity in the United States. JAMA 313:165-173, 2015
31. Adegoke O, Kulasingam S, Virmig B: Cervical cancer trends in the United States: A 35-year population-based analysis. J Womens Health (Larchmt) 21:1031-1037, 2012
32. Shenoy P, Maggioncalda A, Malik N, et al: Incidence patterns and outcomes for Hodgkin lymphoma patients in the United States. Adv Hematol 2011:725219, 2011
33. International Non-Hodgkin’s Lymphoma Prognostic Factors Project: A predictive model for aggressive non-Hodgkin’s lymphoma. N Engl J Med 329:987-994, 1993
34. Hasenclever D, Diehl V: A prognostic score for advanced Hodgkin’s disease: International Prognostic Factors Project on Advanced Hodgkin’s Disease. N Engl J Med 339:1506-1514, 1998
35. Gounder CR, Chaissen RE: A diagonal approach to building primary healthcare systems in resource-limited settings: Women-centred integration of HIV/AIDS, tuberculosis, malaria, MCH and NCD initiatives. Trop Med Int Health 17:1426-1431, 2012
36. Temu F, Leonhardt M, Carter J, et al: Integration of non-communicable diseases in health care: Tackling the double burden of disease in African settings. Pan Afr Med J 18:202, 2014
37. Schneider H, Blauw D, Gilson L, et al: Health systems and access to antiretroviral drugs for HIV in Southern Africa: Service delivery and human resources challenges. Reprod Health Matters 14:12-23, 2006
38. Kober K, Van Damme W: Scaling up access to antiretroviral treatment in southern Africa: Who will do the job? Lancet 364:103-107, 2004
39. Walton DA, Farmer PE, Lambert W, et al: Integrated HIV prevention and care strengthens primary health care: Lessons from rural Haiti. J Public Health Policy 25:137-158, 2004
40. O’Reilly CE, Taylor EV, Ayers T, et al: Improved health among people living with HIV/AIDS who received packages of proven preventive health interventions, Amhara, Ethiopia. PLoS One 9:e107662, 2014
41. Suneja G, Shiels MS, Angulo R, et al: Cancer treatment disparities in HIV-infected individuals in the United States. J Clin Oncol 32:2344-2350, 2014
42. Sigel K, Crothers K, Dubrow R, et al: Prognosis in HIV-infected patients with non-small cell lung cancer. Br J Cancer 109:1974-1980, 2013
43. Maso LD, Suligoi B, Franceschi S, et al: Survival after cancer in Italian persons with AIDS, 1986-2005: A population-based estimation. J Acquir Immune Defic Syndr 66:428-435, 2014
44. Biggar RJ, Engels EA, Ly S, et al: Survival after cancer diagnosis in persons with AIDS. J Acquir Immune Defic Syndr 39:293-299, 2005
45. Achenbach CJ, Cole SR, Kitahata MM, et al: Mortality after cancer diagnosis in HIV-infected individuals treated with antiretroviral therapy. AIDS 25:691-700, 2011
46. Oken MM, Creech RH, Tormey DC, et al: Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5:649-655, 1982
47. Buccheri G, Ferrigno D, Tamburini M: Karnofsky and ECOG performance status scoring in lung cancer: A prospective, longitudinal study of 536 patients from a single institution. Eur J Cancer 32A:1135-1141, 1996
48. Lazebny M, Sebego M, Swart NC, et al: Symptom burden and functional dependencies among cancer patients in Botswana suggest a need for palliative care nursing. Cancer Nurs 39:E29-E38, 2016
49. Reuben DB, Mor V, Hiris J: Clinical symptoms and length of survival in patients with terminal cancer. Arch Intern Med 148:1586-1591, 1988
50. Maltoni M, Pirovano M, Scarpi E, et al: Prediction of survival of patients terminally ill with cancer. Results of an Italian prospective multicentric study. Cancer 75:2613-2622, 1995
51. Hauser CA, Stockler MR, Tattersall MH: Prognostic factors in patients with newly diagnosed incurable cancer: A systematic review. Support Care Cancer 14:999-1011, 2006
52. Moon TD, Silva-Matos C, Cordoso A, et al: Implementation of cervical cancer screening using visual inspection with acetic acid in rural Mozambique: Successes and challenges using HIV care and treatment programme investments in Zambézia Province. J Int AIDS Soc 15:17406, 2012
53. Atashili J, Smith JS, Adimora AA, et al: Potential impact of antiretroviral therapy and screening on cervical cancer mortality in HIV-positive women in sub-Saharan Africa: A simulation. PLoS One 6:e18527, 2011
54. Peto J, Gilham C, Fletcher O, et al: The cervical cancer epidemic that screening has prevented in the UK. Lancet 364:249-256, 2004
55. Nelson HD, Tyne K, Naik A, Bougatsos C, Chan BK, Humphrey L, 2009. Screening for breast cancer: An update for the U.S. Preventive Services Task Force. Ann Intern Med 151: 727-37, w237-w242
56. Goldie SJ, Weinstein MC, Kuntz KM, et al: The costs, clinical benefits, and cost-effectiveness of screening for cervical cancer in HIV-infected women. Ann Intern Med 130:97-107, 1999
57. Goldie SJ, Gaffikin L, Goldhaber-Fiebert JD, et al: Cost-effectiveness of cervical-cancer screening in five developing countries. N Engl J Med 353:2158-2168, 2005